Cervical Intraepithelial Neoplasia Grade 2/3 Clinical Trial
Official title:
Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples and First-void Urine Samples
The "Extended VALHUDES" study is a Clinical Performance / Diagnostic Test Accuracy Study that aims to extend validation, achieved as part of the "Belgian VALHUDES", of HPV testing using BD Onclarity on samples collected using Copan's devices for dry self-sampling of vaginal material and for first-void urine: FLOQSwab® 5E089N and UriSponge™.
Women accessing the Colposcopy Centres for a colposcopy examination and fulfilling the selection criteria will be asked, after written informed consent, to self-collect a first-void urine (with UriSponge™ 8E031S100 device) and a vaginal sample (with FLOQSwab® 5E089N device), prior to undergoing colposcopy. Just before colposcopic examination, a clinician will also collect a cervical sample using a Cervex-Brush. A colposcopy-targeted biopsy or histology following excisional treatment of a cervical precancer lesion will be undertaken if appropriate. The colposcopy and/or histological findings will be used as the gold standard. In case of normal satisfactory colposcopic findings without biopsy taking, colposcopy will provide the study outcome. Virological accuracy of HPV testing using: [a] BD Onclarity on FLOQSwab® 5E089N vaginal self-samples, [b] BD Onclarity on UriSponge™ 8E031S100 urine specimens, will be compared to BD Onclarity testing on a cervical samples collected by a clinician. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03196180 -
Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
|
Early Phase 1 | |
| Active, not recruiting |
NCT04484415 -
Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)
|
Phase 3 | |
| Not yet recruiting |
NCT06258564 -
The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization
|
||
| Not yet recruiting |
NCT06273553 -
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02149030 -
Effectiveness of Cervical Screening in HPV Vaccinated Women
|
Phase 4 | |
| Completed |
NCT01550783 -
Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening
|
N/A | |
| Enrolling by invitation |
NCT04755517 -
Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)
|
N/A | |
| Completed |
NCT02811367 -
The HPV Self-test as a Test of Cure in Madagascar
|
N/A | |
| Completed |
NCT00081263 -
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
|
Phase 2 | |
| Recruiting |
NCT05405270 -
Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
|
||
| Completed |
NCT04312737 -
Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
|
||
| Completed |
NCT02067468 -
Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia
|
N/A | |
| Completed |
NCT02354534 -
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
|
Phase 1 | |
| Recruiting |
NCT03366493 -
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
|
Phase 3 | |
| Active, not recruiting |
NCT03064087 -
Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples
|
||
| Recruiting |
NCT05851079 -
Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
|
||
| Recruiting |
NCT03274206 -
A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
|
Phase 2 |